Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00988715 | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 | 17 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT01793025 | Mismatched Donor Cells to Treat Acute Myeloid Leukemia(ATAC-AML-01) | unknown | Phase 1 | 12 | Maisonneuve-Rosemont HospitalOTHER | 1 |
| Aug 30, 2017 |
| clinicaltrials |
| NCT01947322 | Haploidentical NK-cell Infusion in Acute Myeloid Leukemia(NK) | completed | Phase 1 / Phase 2 | 10 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01169012 | PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias | completed | Phase 1 | 13 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01141725 | Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS | completed | Phase 1 / Phase 2 | 39 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT02255162 | Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML | terminated | Phase 1 | 8 | Massachusetts General HospitalOTHER | 1 | Aug 18, 2017 | clinicaltrials |
| NCT01606579 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | completed | Phase 1 / Phase 2 | 49 | Prism Pharma Co., Ltd.INDUSTRY | 1 | Aug 17, 2017 | clinicaltrials |
| NCT01048827 | Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen(Busulfan) | completed | Phase 1 | 12 | University of California, San FranciscoOTHER | 1 | Aug 11, 2017 | clinicaltrials |
| NCT01034592 | Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia | terminated | Phase 1 | 2 | Jason Robert GotlibOTHER | 1 | Aug 2, 2017 | clinicaltrials |
| NCT01130506 | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2017 | clinicaltrials |
| NCT01961765 | Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 18 | Massachusetts General HospitalOTHER | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00839982 | Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 11, 2017 | clinicaltrials |
| NCT01342887 | Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT01520558 | CNDO-109-AANK for AML in First Complete Remission (CR1) | unknown | Phase 1 / Phase 2 | 12 | Coronado Biosciences, Inc.INDUSTRY | 1 | Jun 29, 2017 | clinicaltrials |
| NCT00854945 | Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML | completed | Phase 1 / Phase 2 | 36 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01167166 | Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) | completed | Phase 1 / Phase 2 | 30 | Traws Pharma, Inc.INDUSTRY | 1 | Jun 26, 2017 | clinicaltrials |
| NCT03114670 | Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT | unknown | Phase 1 | 20 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01483274 | Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation(AML) | withdrawn | Phase 1 | 0 | University of LouisvilleOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT02791919 | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | May 3, 2017 | clinicaltrials |
| NCT01820624 | Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 12 | Paolo Caimi, MDOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT01435343 | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia | completed | Phase 1 / Phase 2 | 55 | PETHEMA FoundationOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00943943 | Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations | completed | Phase 1 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT01398501 | Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Mar 22, 2017 | clinicaltrials |
| NCT00093743 | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia | completed | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01779843 | Alisertib for Acute Myeloid Leukemia | completed | Phase 1 | 22 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 7 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00394381 | Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 17 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT02071927 | Study of the Glutaminase Inhibitor CB-839 in Leukemia | completed | Phase 1 | 43 | Calithera Biosciences, IncINDUSTRY | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01773408 | A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia | completed | Phase 1 | 122 | Hoffmann-La RocheINDUSTRY | 7 | Jan 25, 2017 | clinicaltrials |
| NCT02096289 | Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia(THORIDAL) | completed | Phase 1 | 13 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Dec 7, 2016 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944162 | CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT01635296 | A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 43 | Hoffmann-La RocheINDUSTRY | 5 | Nov 2, 2016 | clinicaltrials |
| NCT01641250 | A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia | completed | Phase 1 | 44 | Hoffmann-La RocheINDUSTRY | 3 | Nov 2, 2016 | clinicaltrials |
| NCT02528877 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | completed | Phase 1 | 10 | Fate TherapeuticsINDUSTRY | 1 | Sep 12, 2016 | clinicaltrials |
| NCT02303782 | A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | withdrawn | Phase 1 / Phase 2 | 0 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 1, 2016 | clinicaltrials |
| NCT01758367 | Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT02859948 | A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | unknown | Phase 1 | 18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 9, 2016 | clinicaltrials |
| NCT01146262 | Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for Acute Myelogenous Leukemia (AML) Patients in First or Second Complete Remission (CR)(CD laM)(CD lam) | unknown | Phase 1 / Phase 2 | 5 | Nantes University HospitalOTHER | 1 | Jul 26, 2016 | clinicaltrials |
| NCT01174888 | Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia | completed | Phase 1 | 34 | Alison WalkerOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT01297543 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | completed | Phase 1 / Phase 2 | 45 | Cellerant TherapeuticsINDUSTRY | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00316030 | Study of Bexarotene in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 54 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 8, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02240537 | Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer(BBMPI03) | unknown | Phase 1 | 4 | Benovus Bio, Inc.INDUSTRY | 1 | Apr 19, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Aug 30, 2017source: clinicaltrials